The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 298, Issue 3, 2010, Pages

  Schreuder, Tim C M A ^a,b   Marsman, Hendrik A ^c   Lenicek, Martin ^d   Van Werven, Jochem R ^c   Nederveen, Aart J ^c   Jansen, Peter L M ^a   Schaap, Frank G ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Department of Surgery ^*  (Netherlands)

^d CHARLES UNIVERSITY   (Czech Republic)

Author keywords

7 hydroxy 4 cholesten 3 one; Bile salt uptake; CYP7A1; Enterohepatic signaling; Postprandial response

Indexed keywords

BILE SALT; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 19; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DYSLIPIDEMIA; FAT INTAKE; FEMALE; HUMAN; INSULIN RESISTANCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN SECRETION; VOLUNTEER;

ADULT; AREA UNDER CURVE; BILE ACIDS AND SALTS; CHOLESTENONES; DIETARY FATS; FATTY LIVER; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; INSULIN RESISTANCE; INTESTINES; LIVER; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; TRIGLYCERIDES;

EID: 77249102583     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00322.2009     Document Type: Article

References (32)

1. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome - a new worldwide definition. Lancet 366: 1059-1062, 2005.
2. American Diabetes Association. Standards of medical care in diabetes - 2007. Diabetes Care 30, Suppl 1: S4-S41, 2007.
3. Andrejko KM, Raj NR, Kim PK, Cereda M, Deutschman CS. IL-6 modulates sepsis-induced decreases in transcription of hepatic organic anion and bile acid transporters. Shock 29: 490-496, 2008.
4. Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol 17, Suppl: S186-S190, 2002.
5. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 8: 235-253, 2009.
6. Bhatnagar S, Damron HA, Hillgartner FB. Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis. J Biol Chem 284: 10023-10033, 2009.
7. Chiang JY. Bile acids: regulation of synthesis. J Lipid Res 50: 1955-1966, 2009.
8. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 114: 842-845, 1998.
9. De Bazelaire CM, Duhamel GD, Rofsky NM, Alsop DC. MR imaging relaxation times of abdominal and pelvic tissues measured in vivo at 3.0 T: preliminary results. Radiology 230: 652-659, 2004.
10. Fisher CD, Lickteig AJ, Augustine LM, Oude Elferink RP, Besselsen DG, Erickson RP, Cherrington NJ. Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats. Eur J Pharmacol 613: 119-127, 2009.
11. Fu L, John LM, Adams SH, Yu XX, Tomlinson E, Renz M, Williams PM, Soriano R, Corpuz R, Moffat B, Vandlen R, Simmons L, Foster J, Stephan JP, Tsai SP, Stewart TA. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 145: 2594-2603, 2004.
12. Gentile CL, Pagliassotti MJ. The role of fatty acids in the development and progression of nonalcoholic fatty liver disease. J Nutr Biochem 19: 567-576, 2008.
13. Hofmann AF. The enterohepatic circulation of bile acids in mammals: form and functions. Front Biosci 14: 2584-2598, 2009.
14. Holt JA, Luo G, Billin AN, Bisi J, McNeill YY, Kozarsky KF, Donahee M, Wang DY, Mansfield TA, Kliewer SA, Goodwin B, Jones SA. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev 17: 1581-1591, 2003.
15. Honda A, Yoshida T, Xu G, Matsuzaki Y, Fukushima S, Tanaka N, Doy M, Shefer S, Salen G. Significance of plasma 7alpha-hydroxy-4-cholesten-3-one and 27-hydroxycholesterol concentrations as markers for hepatic bile acid synthesis in cholesterol-fed rabbits. Metabolism 53: 42-48, 2004.
16. Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, Luo G, Jones SA, Goodwin B, Richardson JA, Gerard RD, Repa JJ, Mangelsdorf DJ, Kliewer SA. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2: 217-225, 2005.
17. Jones S. Mini-review: endocrine actions of fibroblast growth factor 19. Mol Pharm 5: 42-48, 2008.
18. Kim I, Ahn SH, Inagaki T, Choi M, Ito S, Guo GL, Kliewer SA, Gonzalez FJ. Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J Lipid Res 48: 2664-2672, 2007.
19. Lenicek M, Juklova M, Zelenka J, Kovar J, Lukas M, Bortlik M, Vitek L. Improved HPLC analysis of serum 7alpha-hydroxycholest-4-en-3-one, a marker of bile acid malabsorption. Clin Chem 54: 1087-1088, 2008.
20. Liang CP, Tall AR. Transcriptional profiling reveals global defects in energy metabolism, lipoprotein, and bile acid synthesis and transport with reversal by leptin treatment in ob/ob mouse liver. J Biol Chem 276: 49066-49076, 2001.
21. Lundasen T, Galman C, Angelin B, Rudling M. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J Intern Med 260: 530-536, 2006.
22. Marra F, Bertolani C. Adipokines in liver diseases. Hepatology 50: 957-969, 2009.
23. Martins IJ, Redgrave TG. Obesity and post-prandial lipid metabolism. Feast or famine? J Nutr Biochem 15: 130-141, 2004.
24. Nagano M, Kuroki S, Mizuta A, Furukawa M, Noshiro M, Chijiiwa K, Tanaka M. Regulation of bile acid synthesis under reconstructed enterohepatic circulation in rats. Steroids 69: 701-709, 2004.
25. Naressi A, Couturier C, Devos JM, Janssen M, Mangeat C, de Beer R, Graveron-Demilly D. Java-based graphical user interface for the MRUI quantitation package. MAGMA 12: 141-152, 2001.
26. Nierman MC, Rip J, Kuivenhoven JA, van Raalte DH, Hutten BA, Sakai N, Kastelein JJ, Stroes ES. Carriers of the frequent lipoprotein lipase S447X variant exhibit enhanced postprandial apoprotein B-48 clearance. Metabolism 54: 1499-1503, 2005.
27. Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem 72: 137-174, 2003.
28. Schaap FG, van der Gaag NA, Gouma DJ, Jansen PL. High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology 49: 1228-1235, 2009.
29. Shin DJ, Osborne TF. FGF15/FGFR4 integrates growth factor signaling with hepatic bile acid metabolism and insulin action. J Biol Chem 284: 11110-11120, 2009.
30. Stejskal D, Karpisek M, Hanulova Z, Stejskal P. Fibroblast growth factor-19: development, analytical characterization and clinical evaluation of a new ELISA test. Scand J Clin Lab Invest 68: 501-507, 2008.
31. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, Hobbs HH, Dobbins RL. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 288: E462-E468, 2005.
32. Tomlinson E, Fu L, John L, Hultgren B, Huang X, Renz M, Stephan JP, Tsai SP, Powell-Braxton L, French D, Stewart TA. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 143: 1741-1747, 2002.